Monash IVF Group (MIS) 주식 개요모나쉬 IVF 그룹은 호주와 말레이시아에서 보조 생식술 및 전문 여성 영상 서비스를 제공합니다. 자세히 보기MIS 펀더멘털 분석스노우플레이크 점수가치 평가4/6미래 성장1/6과거 실적2/6재무 건전성3/6배당3/6강점공정 가치 추정치보다 낮은 69% 에서 거래수익은 매년 16.54% 증가할 것으로 예상됩니다.올해부터 흑자전환위험 분석7.22% 의 배당금은 잉여현금흐름으로 잘 충당되지 않습니다.지난 3개월 동안 주가 변동성이 German 시장과 비교해 높았습니다.모든 위험 점검 보기MIS Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.417.4% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-2m309m2016201920222025202620282031Revenue AU$309.2mEarnings AU$17.4mAdvancedSet Fair ValueView all narrativesMonash IVF Group Limited 경쟁사LIMES SchlossklinikenSymbol: XTRA:LIKMarket cap: €160.9mMEDICLINSymbol: XTRA:MEDMarket cap: €188.1mM1 KlinikenSymbol: XTRA:M12Market cap: €351.4mRHÖN-KLINIKUMSymbol: XTRA:RHKMarket cap: €863.5m가격 이력 및 성과Monash IVF Group 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가AU$0.4152주 최고가AU$0.4852주 최저가AU$0.32베타0.391개월 변동0.49%3개월 변동7.37%1년 변동11.48%3년 변동-40.44%5년 변동-22.29%IPO 이후 변동-64.49%최근 뉴스 및 업데이트공시 • Apr 20WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF).WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.85 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. As of April 13, 2026 Monash IVF Group Limited has now received a revised, unsolicited, conditional and non-binding indicative proposal from WHSP Holdings Limited (ASX:SOL) and Genesis Capital. The indicative cash price offered to shareholders under the Proposal is AUD 0.90 per share. As part part of consideration AUD 281.93 million is paid towards common equity and AUD 1.68 million is paid towards performance rights. It should be noted that there is no certainty that the discussions with the Consortium will result in any transaction. If there are material developments in the future, Monash IVF will inform shareholders as required under its continuous disclosure obligations. The deal is conditional upon exclusive due diligence, including a 4-week period of exclusivity with no fiduciary exceptions, negotiation and execution of transaction documentation on 'customary terms', including a no material adverse change condition, unanimous recommendation of the Monash IVF Board of the Proposal and final internal approval from the relevant Consortium Members for a final binding proposal and entry into transaction documentation. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF) on April 20, 2026. Monash IVF Group Limited announced that its Board has unanimously rejected the revised non-binding proposal from Genesis Capital and Soul Patts to acquire the company for AUD 0.90 per share, stating the offer undervalues the company but remains open to a higher bid. This captures the rejection, the offer price, the reason, and the fact that the door remains open for a higher offer, which are the key takeaways for our tracking purposes.공시 • Feb 26Monash IVF Group Limited Announces Ordinary Fully Franked Interim Dividend for the Period Ended December 31, 2025, Payable on 10 April 2026Monash IVF Group Limited announced ordinary fully franked interim dividend of AUD 0.01200000 per share for the period ended December 31, 2025. The record date for the dividend is 5 March 2026 and the payment date is 10 April 2026. Ex date is March 4, 2026.공시 • Jan 27+ 1 more updateMonash IVF Group Limited Announces Resignation of Malik Jainudeen as Company Secretary, Effective End of April 2026Monash IVF Group Limited announced the resignation of Company Secretary, Mr. Malik Jainudeen. Mr. Jainudeen will remain with Monash IVF Group until the end of April 2026 before he commences his new role at another organisation. Malik Jainudeen has made significant contributions since joining Monash IVF Group in 2014, including stepping into the Acting CEO role during the last six months.공시 • Jan 23Monash IVF Group Limited to Report Fiscal Year 2026 Results on Aug 24, 2026Monash IVF Group Limited announced that they will report fiscal year 2026 results on Aug 24, 2026공시 • Jan 20Monash IVF Group Limited to Report First Half, 2026 Results on Feb 26, 2026Monash IVF Group Limited announced that they will report first half, 2026 results on Feb 26, 2026공시 • Nov 24WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million.WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.8 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) on November 24, 2025.더 많은 업데이트 보기Recent updates공시 • Apr 20WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF).WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.85 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. As of April 13, 2026 Monash IVF Group Limited has now received a revised, unsolicited, conditional and non-binding indicative proposal from WHSP Holdings Limited (ASX:SOL) and Genesis Capital. The indicative cash price offered to shareholders under the Proposal is AUD 0.90 per share. As part part of consideration AUD 281.93 million is paid towards common equity and AUD 1.68 million is paid towards performance rights. It should be noted that there is no certainty that the discussions with the Consortium will result in any transaction. If there are material developments in the future, Monash IVF will inform shareholders as required under its continuous disclosure obligations. The deal is conditional upon exclusive due diligence, including a 4-week period of exclusivity with no fiduciary exceptions, negotiation and execution of transaction documentation on 'customary terms', including a no material adverse change condition, unanimous recommendation of the Monash IVF Board of the Proposal and final internal approval from the relevant Consortium Members for a final binding proposal and entry into transaction documentation. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF) on April 20, 2026. Monash IVF Group Limited announced that its Board has unanimously rejected the revised non-binding proposal from Genesis Capital and Soul Patts to acquire the company for AUD 0.90 per share, stating the offer undervalues the company but remains open to a higher bid. This captures the rejection, the offer price, the reason, and the fact that the door remains open for a higher offer, which are the key takeaways for our tracking purposes.공시 • Feb 26Monash IVF Group Limited Announces Ordinary Fully Franked Interim Dividend for the Period Ended December 31, 2025, Payable on 10 April 2026Monash IVF Group Limited announced ordinary fully franked interim dividend of AUD 0.01200000 per share for the period ended December 31, 2025. The record date for the dividend is 5 March 2026 and the payment date is 10 April 2026. Ex date is March 4, 2026.공시 • Jan 27+ 1 more updateMonash IVF Group Limited Announces Resignation of Malik Jainudeen as Company Secretary, Effective End of April 2026Monash IVF Group Limited announced the resignation of Company Secretary, Mr. Malik Jainudeen. Mr. Jainudeen will remain with Monash IVF Group until the end of April 2026 before he commences his new role at another organisation. Malik Jainudeen has made significant contributions since joining Monash IVF Group in 2014, including stepping into the Acting CEO role during the last six months.공시 • Jan 23Monash IVF Group Limited to Report Fiscal Year 2026 Results on Aug 24, 2026Monash IVF Group Limited announced that they will report fiscal year 2026 results on Aug 24, 2026공시 • Jan 20Monash IVF Group Limited to Report First Half, 2026 Results on Feb 26, 2026Monash IVF Group Limited announced that they will report first half, 2026 results on Feb 26, 2026공시 • Nov 24WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million.WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.8 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) on November 24, 2025.공시 • Oct 20Monash IVF Group Limited, Annual General Meeting, Nov 20, 2025Monash IVF Group Limited, Annual General Meeting, Nov 20, 2025. Location: kpmg tower two, level 36, meeting room 36.17, collins square, 727 collins street, melbourne vic 3008 Australia공시 • Jun 12+ 1 more updateMonash IVF Group Limited Announces CEO ChangesMonash IVF Group Limited's Board has on June 12, 2025 accepted Michael Knaap's resignation as Chief Executive Officer of the company. Since his appointment in 2019, Michael has led the organisation through a period of significant growth and transformation, and The company thanks him for his years of dedicated service. Monash IVF Group Chief Financial Officer and Company Secretary, Malik Jainudeen has been appointed as Acting Chief Executive Officer. Malik Jainudeen brings over a decade of service to Monash IVF Group, having joined in 2014 and serving as Chief Financial Officer and Company Secretary since 2019. His deep understanding of the organisation's operations, positions him as a steady and capable leader during this transitional period. With a background that includes ten years at KPMG managing audits for major ASX-listed companies, Malik combines financial understanding with a comprehensive knowledge of the healthcare sector.공시 • Mar 01Monash IVF Group Limited Declares Fully Franked Interim Dividend for the First Half ended 31 December 2024, Payable on 11 April 2025Monash IVF Group Limited declared fully franked interim dividend for the first half ended 31 December 2024 of 2.6 cents per share. The record date for the dividend is 7 March 2025 and the payment date is 11 April 2025.공시 • Jan 13+ 1 more updateMonash IVF Group Limited to Report Fiscal Year 2025 Results on Aug 22, 2025Monash IVF Group Limited announced that they will report fiscal year 2025 results on Aug 22, 2025Board Change • Dec 30Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Cathy Aston was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.New Risk • Oct 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite being loss-making. Share price has been volatile over the past 3 months (7.1% average weekly change).공시 • Sep 25Monash IVF Group Limited Announces Board ChangesMonash IVF Group Limited advised that Mr. Josef Czyzewski has tendered his resignation as a non-executive director. Mr. Czyzewski was appointed as a non-executive director of the Company on 4 June 2014 and has been a valuable member of the Board, Chair of the Audit & Risk Management Committee and a member of the Remuneration and Nomination Committee since commencement. Mr. Czyzewski will cease being a non-executive director of the Company on 31 October 2024. Ms Catherine Aston, who was appointed as a non-executive director of Monash IVF Group on 26 February 2024, will be appointed as Chair to the Audit & Risk Management Committee and will be a member of the Remuneration and Nomination Committee, effective from 31 October 2024.Recent Insider Transactions • Sep 18Independent Non-Executive Director recently bought €57k worth of stockOn the 16th of September, Catherine Aston bought around 77k shares on-market at roughly €0.73 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.공시 • Aug 24+ 1 more updateMonash IVF Group Limited Announces Ordinary Fully Franked Dividend for the Six Months Ended June 30, 2024, Payable on October 11, 2024Monash IVF Group Limited announced Ordinary fully franked dividend of AUD 0.02500000 per share for the six months ended June 30, 2024. Record Date is September 6, 2024. Ex Date is September 5, 2024. Payment Date is October 11, 2024.Reported Earnings • Aug 23Full year 2024 earnings released: AU$0.017 loss per share (vs AU$0.056 profit in FY 2023)Full year 2024 results: AU$0.017 loss per share (down from AU$0.056 profit in FY 2023). Revenue: AU$255.2m (up 20% from FY 2023). Net loss: AU$6.53m (down 130% from profit in FY 2023). Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.공시 • Mar 05Monash IVF Group Limited (ASX:MVF)completed the acquisition of 80% stake in Fertility North Holdings Pty Ltd.Monash IVF Group Limited (ASX:MVF) entered into Share Sale Agreement to acquire 80% stake in Fertility North Holdings Pty Ltd on December 19, 2023. The consideration for initial up-front cash consideration is estimated at AUD 12 million. Additional earn-out payments over a one to three year period may be payable, based on the achievement of certain financial targets. The AUD 0.5 million acquisition costs incurred by Monash for the half year ended December 31, 2023 includes the Fertility North acquisition. Fertility North generates approximately AUD 9 million revenue per annum. The acquisition is subject to certain conditions precedent, including Australian Competition and Consumer Commission (ACCC) approval. As of February 22, 2024, Australian Competition and Consumer Commission approved the transaction. The completion of the deal is anticipated to occur in Q3 FY24. Monash IVF Group Limited (ASX:MVF) completed the acquisition of 80% stake in Fertility North Holdings Pty Ltd on March 4, 2024.Upcoming Dividend • Feb 29Upcoming dividend of AU$0.025 per shareEligible shareholders must have bought the stock before 07 March 2024. Payment date: 05 April 2024. Payout ratio is a comfortable 73% and the cash payout ratio is 76%. Trailing yield: 3.1%. Lower than top quartile of German dividend payers (5.2%). In line with average of industry peers (3.3%).공시 • Feb 28Monash IVF Group Limited Appoints Cathy Aston as an Independent Non-Executive Director and A Member of the Audit and Risk Management Committee Effective from 26 February 2024Monash IVF Group Limited announced the appointment of Ms. Cathy Aston as an Independent Non-Executive Director and a member of the Audit and Risk Management Committee effective from 26 February 2024. Cathy is an experienced ASX listed non-executive director and has over 20 years' experience in executive roles across finance, marketing, strategy and technology, both in Australia and Asia. Cathy is very familiar with the IVF industry, serving on the Board of Virtus Health until its takeover in 2022. Cathy's executive roles were in the telecommunications industry, predominantly at Telstra where she worked for over 20 years. During her time at Telstra her senior roles were varied, initially focussing on finance, and over time transitioning to strategic roles across marketing, customer experience and technology. A key focus for Cathy was enabling businesses to improve their service offerings and customer experience through the use of technology. Cathy has significant experience in international expansion, in particularly in Asia, having worked in Hong Kong, Sri Lanka and India. Over the past decade Cathy has been very active in non-executive and advisory roles. Cathy is a non- executive director of ASX listed Integrated Research (Chair of the Audit and Risk Committee), IVE Group (Chair of the Risk and Compliance Committee), Macquarie Investment Management (Chair of the Audit, Risk and Compliance Committee) and IMB Bank (Chair). Previously she was on the Board of Virtus Health. Cathy's advisory roles have included work with the NSW State Government, and an Advisory Board Member of Avanseus, a Singapore based AI business. Cathy has a Bachelor of Economics (Macquarie University) and a Master of Commerce, Accounting & Law (University of NSW). She is a Graduate of the Australian Institute of Company Directors and a Senior Fellow of the Financial Services Institute of Australasia (FINSIA).Reported Earnings • Feb 27First half 2024 earnings released: EPS: AU$0.033 (vs AU$0.027 in 1H 2023)First half 2024 results: EPS: AU$0.033 (up from AU$0.027 in 1H 2023). Revenue: AU$125.7m (up 22% from 1H 2023). Net income: AU$12.8m (up 20% from 1H 2023). Profit margin: 10% (in line with 1H 2023). Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, while revenues in the Healthcare industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings.Declared Dividend • Feb 26First half dividend of AU$0.025 announcedShareholders will receive a dividend of AU$0.025. Ex-date: 7th March 2024 Payment date: 5th April 2024 Dividend yield will be 4.5%, which is higher than the industry average of 3.3%. Sustainability & Growth Dividend is covered by both earnings (73% earnings payout ratio) and cash flows (80% cash payout ratio). The dividend has decreased over the past 96 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 51% over the next 3 years, which should provide support to the dividend and adequate earnings cover.공시 • Jan 08+ 1 more updateMonash IVF Group Limited to Report First Half, 2024 Results on Feb 23, 2024Monash IVF Group Limited announced that they will report first half, 2024 results on Feb 23, 2024Upcoming Dividend • Aug 31Upcoming dividend of AU$0.022 per share at 3.5% yieldEligible shareholders must have bought the stock before 07 September 2023. Payment date: 11 October 2023. Payout ratio is on the higher end at 79%, and the cash payout ratio is above 100%. Trailing yield: 3.5%. Lower than top quartile of German dividend payers (4.9%). Higher than average of industry peers (2.9%).공시 • Aug 22Monash IVF Group Limited Announces Fully Franked Final Dividend for Fiscal Year Ended June 30, 2023, Payable on 11 October 2023Monash IVF Group Limited announced that on 22 August 2023, a fully franked final FY2023 dividend of 2.2 cents per share was declared. The record date for the dividend is 8 September 2023 and the payment date for the dividend is 11 October 2023.Reported Earnings • Aug 22Full year 2023 earnings released: EPS: AU$0.056 (vs AU$0.047 in FY 2022)Full year 2023 results: EPS: AU$0.056 (up from AU$0.047 in FY 2022). Revenue: AU$213.6m (up 11% from FY 2022). Net income: AU$21.8m (up 19% from FY 2022). Profit margin: 10% (in line with FY 2022). Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.공시 • Aug 21Monash IVF Group Limited Provides Update on Class Action LawsuitAs announced to the ASX on 23 December 2020, Monash IVF Group Limited became aware that it and certain of its subsidiaries have been named as defendants ("Defendants") in proceedings filed in the Supreme Court of Victoria in relation to, or in connection with, the Group's non-invasive pre-implantation genetic screening technology (Ni-PGT or cell-free PGT-A) ("Class Action"). The plaintiffs in the Class Action have filed an amended statement of claim in relation to the Class Action. The amended statement of claim, amongst other things, seeks payment for aggravated damages and exemplary damages from the Defendants in the Class Action. No amount is specified or estimated in respect of the claim. As previously announced, Monash IVF has notified its insurer. The costs of Monash IVF's defence of the Class Action are currently being funded by its insurer. The amended part of the Class Action relating to aggravated damages and exemplary damages, and the costs of defending that, is uninsured. Legal costs and damages, if any, in excess of insurance proceeds will be funded by Monash IVF. Monash IVF continues to defend these claims and will keep the market updated in regards to its continuous disclosure obligations.공시 • May 29Monash IVF Group Limited (ASX:MVF) completed the acquisition of PIVET Medical Centre.Monash IVF Group Limited (ASX:MVF) agreed to acquire PIVET Medical Centre for AUD 9.4 million on May 18, 2022. Monash IVF is paying additional earn out payments over a one to two year period from completion. The acquisition is expected to be funded through Monash IVF's operating cash flows and/or debt facilities available. The PIVET brings into the Monash IVF clinician network, 9 fertility specialists who have worked together for several years. Completion is expected to occur during First Quarter 2023, subject to certain conditions precedent. As of August 26, 2022, The transaction is expected to complete by end of September 2022. As of February 21, 2023, the transaction is expected to complete by end of Q3 of FY2023. Squire Patton Boggs (UK) LLP acted as a legal advisor to PIVET Medical Centre. Monash IVF Group Limited (ASX:MVF) completed the acquisition of PIVET Medical Centre on May 29, 2023.Upcoming Dividend • Mar 01Upcoming dividend of AU$0.022 per share at 4.2% yieldEligible shareholders must have bought the stock before 08 March 2023. Payment date: 06 April 2023. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 4.2%. Lower than top quartile of German dividend payers (4.7%). Higher than average of industry peers (3.3%).Reported Earnings • Feb 21First half 2023 earnings released: EPS: AU$0.027 (vs AU$0.031 in 1H 2022)First half 2023 results: EPS: AU$0.027 (down from AU$0.031 in 1H 2022). Revenue: AU$103.3m (up 2.3% from 1H 2022). Net income: AU$10.6m (down 12% from 1H 2022). Profit margin: 10% (down from 12% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.3% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.공시 • Jan 18+ 2 more updatesMonash IVF Group Limited to Report First Half, 2023 Results on Feb 21, 2023Monash IVF Group Limited announced that they will report first half, 2023 results on Feb 21, 2023Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Catherine West was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Upcoming Dividend • Sep 01Upcoming dividend of AU$0.022 per shareEligible shareholders must have bought the stock before 08 September 2022. Payment date: 07 October 2022. Payout ratio and cash payout ratio are on the higher end at 93% and 83% respectively. Trailing yield: 4.3%. Lower than top quartile of German dividend payers (4.7%). Higher than average of industry peers (3.7%).Reported Earnings • Aug 27Full year 2022 earnings released: EPS: AU$0.047 (vs AU$0.065 in FY 2021)Full year 2022 results: EPS: AU$0.047 (down from AU$0.065 in FY 2021). Revenue: AU$192.3m (up 4.7% from FY 2021). Net income: AU$18.4m (down 27% from FY 2021). Profit margin: 9.6% (down from 14% in FY 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 13%, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.Board Change • Jun 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Non-Executive Director Catherine West was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • May 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Non-Executive Director Catherine West was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Upcoming Dividend • Sep 02Upcoming dividend of AU$0.021 per shareEligible shareholders must have bought the stock before 09 September 2021. Payment date: 08 October 2021. Trailing yield: 4.2%. Within top quartile of German dividend payers (3.1%). Higher than average of industry peers (2.2%).Reported Earnings • Aug 25Full year 2021 earnings released: EPS AU$0.065 (vs AU$0.046 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$183.6m (up 26% from FY 2020). Net income: AU$25.1m (up 115% from FY 2020). Profit margin: 14% (up from 8.1% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.Recent Insider Transactions • May 01Independent Non-Executive Director recently bought €124k worth of stockOn the 26th of April, Neil Broekhuizen bought around 217k shares on-market at roughly €0.57 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €146k more in shares than they have sold in the last 12 months.Analyst Estimate Surprise Post Earnings • Feb 25Revenue beats expectationsRevenue exceeded analyst estimates by 4.3%. Over the next year, revenue is forecast to grow 6.0%, compared to a 3.4% growth forecast for the Healthcare industry in Germany.Reported Earnings • Feb 25First half 2021 earnings released: EPS AU$0.037 (vs AU$0.035 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: AU$90.8m (up 18% from 1H 2020). Net income: AU$14.6m (up 79% from 1H 2020). Profit margin: 16% (up from 11% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Feb 18New 90-day high: €0.51The company is up 11% from its price of €0.46 on 19 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.56 per share.Is New 90 Day High Low • Dec 23New 90-day high: €0.48The company is up 39% from its price of €0.34 on 24 September 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.53 per share.Is New 90 Day High Low • Nov 11New 90-day high: €0.44The company is up 38% from its price of €0.32 on 13 August 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.45 per share.주주 수익률MISDE HealthcareDE 시장7D0%-1.4%-2.4%1Y11.5%-10.3%-0.6%전체 주주 수익률 보기수익률 대 산업: MIS은 지난 1년 동안 -10.3%의 수익을 기록한 German Healthcare 산업보다 더 좋은 성과를 냈습니다.수익률 대 시장: MIS은 지난 1년 동안 -0.6%를 기록한 German 시장보다 더 좋은 성과를 냈습니다.주가 변동성Is MIS's price volatile compared to industry and market?MIS volatilityMIS Average Weekly Movement8.3%Healthcare Industry Average Movement5.5%Market Average Movement5.7%10% most volatile stocks in DE Market13.3%10% least volatile stocks in DE Market2.8%안정적인 주가: MIS의 주가는 지난 3개월 동안 German 시장보다 변동성이 컸습니다.시간에 따른 변동성: MIS의 주간 변동성(8%)은 지난 1년 동안 안정적이었지만 German 종목 중 상위 75%보다 높습니다.회사 소개설립직원 수CEO웹사이트2014892Victoria Atkinsonwww.monashivfgroup.com.au모나쉬 IVF 그룹은 호주와 말레이시아에서 보조 생식술 및 전문 여성 영상 서비스를 제공합니다. 이 회사는 진단 산부인과, 부인과 초음파 및 불임 치료 서비스를 제공합니다. 또한 3차 수준의 산전 진단 및 시험관 아기 치료 서비스도 제공합니다.더 보기Monash IVF Group Limited 기초 지표 요약Monash IVF Group의 순이익과 매출은 시가총액과 어떻게 비교됩니까?MIS 기초 통계시가총액€169.15m순이익 (TTM)€9.14m매출 (TTM)€162.43m18.5x주가수익비율(P/E)1.0x주가매출비율(P/S)MIS는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표MIS 손익계산서 (TTM)매출AU$269.39m매출원가AU$185.18m총이익AU$84.22m기타 비용AU$69.06m순이익AU$15.16m최근 보고된 실적Dec 31, 2025다음 실적 발표일Aug 24, 2026주당순이익(EPS)0.039총이익률31.26%순이익률5.63%부채/자본 비율39.8%MIS의 장기 실적은 어땠습니까?과거 실적 및 비교 보기배당7.2%현재 배당 수익률31%배당 성향View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/29 12:03종가2026/06/29 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Monash IVF Group Limited는 14명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Martyn JacobsBell PotterBradley WatsonBell PotterTara SperanzaBell Potter11명의 분석가 더 보기
공시 • Apr 20WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF).WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.85 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. As of April 13, 2026 Monash IVF Group Limited has now received a revised, unsolicited, conditional and non-binding indicative proposal from WHSP Holdings Limited (ASX:SOL) and Genesis Capital. The indicative cash price offered to shareholders under the Proposal is AUD 0.90 per share. As part part of consideration AUD 281.93 million is paid towards common equity and AUD 1.68 million is paid towards performance rights. It should be noted that there is no certainty that the discussions with the Consortium will result in any transaction. If there are material developments in the future, Monash IVF will inform shareholders as required under its continuous disclosure obligations. The deal is conditional upon exclusive due diligence, including a 4-week period of exclusivity with no fiduciary exceptions, negotiation and execution of transaction documentation on 'customary terms', including a no material adverse change condition, unanimous recommendation of the Monash IVF Board of the Proposal and final internal approval from the relevant Consortium Members for a final binding proposal and entry into transaction documentation. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF) on April 20, 2026. Monash IVF Group Limited announced that its Board has unanimously rejected the revised non-binding proposal from Genesis Capital and Soul Patts to acquire the company for AUD 0.90 per share, stating the offer undervalues the company but remains open to a higher bid. This captures the rejection, the offer price, the reason, and the fact that the door remains open for a higher offer, which are the key takeaways for our tracking purposes.
공시 • Feb 26Monash IVF Group Limited Announces Ordinary Fully Franked Interim Dividend for the Period Ended December 31, 2025, Payable on 10 April 2026Monash IVF Group Limited announced ordinary fully franked interim dividend of AUD 0.01200000 per share for the period ended December 31, 2025. The record date for the dividend is 5 March 2026 and the payment date is 10 April 2026. Ex date is March 4, 2026.
공시 • Jan 27+ 1 more updateMonash IVF Group Limited Announces Resignation of Malik Jainudeen as Company Secretary, Effective End of April 2026Monash IVF Group Limited announced the resignation of Company Secretary, Mr. Malik Jainudeen. Mr. Jainudeen will remain with Monash IVF Group until the end of April 2026 before he commences his new role at another organisation. Malik Jainudeen has made significant contributions since joining Monash IVF Group in 2014, including stepping into the Acting CEO role during the last six months.
공시 • Jan 23Monash IVF Group Limited to Report Fiscal Year 2026 Results on Aug 24, 2026Monash IVF Group Limited announced that they will report fiscal year 2026 results on Aug 24, 2026
공시 • Jan 20Monash IVF Group Limited to Report First Half, 2026 Results on Feb 26, 2026Monash IVF Group Limited announced that they will report first half, 2026 results on Feb 26, 2026
공시 • Nov 24WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million.WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.8 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) on November 24, 2025.
공시 • Apr 20WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF).WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.85 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. As of April 13, 2026 Monash IVF Group Limited has now received a revised, unsolicited, conditional and non-binding indicative proposal from WHSP Holdings Limited (ASX:SOL) and Genesis Capital. The indicative cash price offered to shareholders under the Proposal is AUD 0.90 per share. As part part of consideration AUD 281.93 million is paid towards common equity and AUD 1.68 million is paid towards performance rights. It should be noted that there is no certainty that the discussions with the Consortium will result in any transaction. If there are material developments in the future, Monash IVF will inform shareholders as required under its continuous disclosure obligations. The deal is conditional upon exclusive due diligence, including a 4-week period of exclusivity with no fiduciary exceptions, negotiation and execution of transaction documentation on 'customary terms', including a no material adverse change condition, unanimous recommendation of the Monash IVF Board of the Proposal and final internal approval from the relevant Consortium Members for a final binding proposal and entry into transaction documentation. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of 80.4% stake in Monash IVF Group Limited (ASX:MVF) on April 20, 2026. Monash IVF Group Limited announced that its Board has unanimously rejected the revised non-binding proposal from Genesis Capital and Soul Patts to acquire the company for AUD 0.90 per share, stating the offer undervalues the company but remains open to a higher bid. This captures the rejection, the offer price, the reason, and the fact that the door remains open for a higher offer, which are the key takeaways for our tracking purposes.
공시 • Feb 26Monash IVF Group Limited Announces Ordinary Fully Franked Interim Dividend for the Period Ended December 31, 2025, Payable on 10 April 2026Monash IVF Group Limited announced ordinary fully franked interim dividend of AUD 0.01200000 per share for the period ended December 31, 2025. The record date for the dividend is 5 March 2026 and the payment date is 10 April 2026. Ex date is March 4, 2026.
공시 • Jan 27+ 1 more updateMonash IVF Group Limited Announces Resignation of Malik Jainudeen as Company Secretary, Effective End of April 2026Monash IVF Group Limited announced the resignation of Company Secretary, Mr. Malik Jainudeen. Mr. Jainudeen will remain with Monash IVF Group until the end of April 2026 before he commences his new role at another organisation. Malik Jainudeen has made significant contributions since joining Monash IVF Group in 2014, including stepping into the Acting CEO role during the last six months.
공시 • Jan 23Monash IVF Group Limited to Report Fiscal Year 2026 Results on Aug 24, 2026Monash IVF Group Limited announced that they will report fiscal year 2026 results on Aug 24, 2026
공시 • Jan 20Monash IVF Group Limited to Report First Half, 2026 Results on Feb 26, 2026Monash IVF Group Limited announced that they will report first half, 2026 results on Feb 26, 2026
공시 • Nov 24WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million.WHSP Holdings Limited (ASX:SOL) and Genesis Capital entered into a non-binding indicative proposal to acquire remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) for approximately AUD 250 million on November 24, 2025. A cash consideration valued at AUD 0.8 per share and will be paid by WHSP Holdings Limited and Genesis Capital. As part of consideration, an AUD 0.8 million is paid towards Performance Rights and AUD 250.61 million is paid towards common equity of Monash IVF Group Limited. The transaction is contingent upon exclusive due diligence, customary transaction documentation negotiation and execution, unanimous Monash IVF Group Limited recommendation, and final internal approval from WHSP Holdings Limited and Genesis Capital for a binding proposal and transaction documentation. The deal has been rejected by the board of Monash IVF Group Limited due to the Offer Price being at a substantial discount to comparable IVF transactions in the Australian market, the Proposal remaining conditional and requiring further due diligence and access to senior management and key employees, and uncertainty regarding the financing arrangements proposed by the Consortium. Macquarie Capital Limited acted as financial advisor for Monash IVF Group Limited. Clayton Utz acted as legal advisor for Monash IVF Group Limited. WHSP Holdings Limited (ASX:SOL) and Genesis Capital cancelled the acquisition of remaining 80.4% stake in Monash IVF Group Limited (ASX:MVF) on November 24, 2025.
공시 • Oct 20Monash IVF Group Limited, Annual General Meeting, Nov 20, 2025Monash IVF Group Limited, Annual General Meeting, Nov 20, 2025. Location: kpmg tower two, level 36, meeting room 36.17, collins square, 727 collins street, melbourne vic 3008 Australia
공시 • Jun 12+ 1 more updateMonash IVF Group Limited Announces CEO ChangesMonash IVF Group Limited's Board has on June 12, 2025 accepted Michael Knaap's resignation as Chief Executive Officer of the company. Since his appointment in 2019, Michael has led the organisation through a period of significant growth and transformation, and The company thanks him for his years of dedicated service. Monash IVF Group Chief Financial Officer and Company Secretary, Malik Jainudeen has been appointed as Acting Chief Executive Officer. Malik Jainudeen brings over a decade of service to Monash IVF Group, having joined in 2014 and serving as Chief Financial Officer and Company Secretary since 2019. His deep understanding of the organisation's operations, positions him as a steady and capable leader during this transitional period. With a background that includes ten years at KPMG managing audits for major ASX-listed companies, Malik combines financial understanding with a comprehensive knowledge of the healthcare sector.
공시 • Mar 01Monash IVF Group Limited Declares Fully Franked Interim Dividend for the First Half ended 31 December 2024, Payable on 11 April 2025Monash IVF Group Limited declared fully franked interim dividend for the first half ended 31 December 2024 of 2.6 cents per share. The record date for the dividend is 7 March 2025 and the payment date is 11 April 2025.
공시 • Jan 13+ 1 more updateMonash IVF Group Limited to Report Fiscal Year 2025 Results on Aug 22, 2025Monash IVF Group Limited announced that they will report fiscal year 2025 results on Aug 22, 2025
Board Change • Dec 30Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Cathy Aston was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
New Risk • Oct 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite being loss-making. Share price has been volatile over the past 3 months (7.1% average weekly change).
공시 • Sep 25Monash IVF Group Limited Announces Board ChangesMonash IVF Group Limited advised that Mr. Josef Czyzewski has tendered his resignation as a non-executive director. Mr. Czyzewski was appointed as a non-executive director of the Company on 4 June 2014 and has been a valuable member of the Board, Chair of the Audit & Risk Management Committee and a member of the Remuneration and Nomination Committee since commencement. Mr. Czyzewski will cease being a non-executive director of the Company on 31 October 2024. Ms Catherine Aston, who was appointed as a non-executive director of Monash IVF Group on 26 February 2024, will be appointed as Chair to the Audit & Risk Management Committee and will be a member of the Remuneration and Nomination Committee, effective from 31 October 2024.
Recent Insider Transactions • Sep 18Independent Non-Executive Director recently bought €57k worth of stockOn the 16th of September, Catherine Aston bought around 77k shares on-market at roughly €0.73 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
공시 • Aug 24+ 1 more updateMonash IVF Group Limited Announces Ordinary Fully Franked Dividend for the Six Months Ended June 30, 2024, Payable on October 11, 2024Monash IVF Group Limited announced Ordinary fully franked dividend of AUD 0.02500000 per share for the six months ended June 30, 2024. Record Date is September 6, 2024. Ex Date is September 5, 2024. Payment Date is October 11, 2024.
Reported Earnings • Aug 23Full year 2024 earnings released: AU$0.017 loss per share (vs AU$0.056 profit in FY 2023)Full year 2024 results: AU$0.017 loss per share (down from AU$0.056 profit in FY 2023). Revenue: AU$255.2m (up 20% from FY 2023). Net loss: AU$6.53m (down 130% from profit in FY 2023). Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
공시 • Mar 05Monash IVF Group Limited (ASX:MVF)completed the acquisition of 80% stake in Fertility North Holdings Pty Ltd.Monash IVF Group Limited (ASX:MVF) entered into Share Sale Agreement to acquire 80% stake in Fertility North Holdings Pty Ltd on December 19, 2023. The consideration for initial up-front cash consideration is estimated at AUD 12 million. Additional earn-out payments over a one to three year period may be payable, based on the achievement of certain financial targets. The AUD 0.5 million acquisition costs incurred by Monash for the half year ended December 31, 2023 includes the Fertility North acquisition. Fertility North generates approximately AUD 9 million revenue per annum. The acquisition is subject to certain conditions precedent, including Australian Competition and Consumer Commission (ACCC) approval. As of February 22, 2024, Australian Competition and Consumer Commission approved the transaction. The completion of the deal is anticipated to occur in Q3 FY24. Monash IVF Group Limited (ASX:MVF) completed the acquisition of 80% stake in Fertility North Holdings Pty Ltd on March 4, 2024.
Upcoming Dividend • Feb 29Upcoming dividend of AU$0.025 per shareEligible shareholders must have bought the stock before 07 March 2024. Payment date: 05 April 2024. Payout ratio is a comfortable 73% and the cash payout ratio is 76%. Trailing yield: 3.1%. Lower than top quartile of German dividend payers (5.2%). In line with average of industry peers (3.3%).
공시 • Feb 28Monash IVF Group Limited Appoints Cathy Aston as an Independent Non-Executive Director and A Member of the Audit and Risk Management Committee Effective from 26 February 2024Monash IVF Group Limited announced the appointment of Ms. Cathy Aston as an Independent Non-Executive Director and a member of the Audit and Risk Management Committee effective from 26 February 2024. Cathy is an experienced ASX listed non-executive director and has over 20 years' experience in executive roles across finance, marketing, strategy and technology, both in Australia and Asia. Cathy is very familiar with the IVF industry, serving on the Board of Virtus Health until its takeover in 2022. Cathy's executive roles were in the telecommunications industry, predominantly at Telstra where she worked for over 20 years. During her time at Telstra her senior roles were varied, initially focussing on finance, and over time transitioning to strategic roles across marketing, customer experience and technology. A key focus for Cathy was enabling businesses to improve their service offerings and customer experience through the use of technology. Cathy has significant experience in international expansion, in particularly in Asia, having worked in Hong Kong, Sri Lanka and India. Over the past decade Cathy has been very active in non-executive and advisory roles. Cathy is a non- executive director of ASX listed Integrated Research (Chair of the Audit and Risk Committee), IVE Group (Chair of the Risk and Compliance Committee), Macquarie Investment Management (Chair of the Audit, Risk and Compliance Committee) and IMB Bank (Chair). Previously she was on the Board of Virtus Health. Cathy's advisory roles have included work with the NSW State Government, and an Advisory Board Member of Avanseus, a Singapore based AI business. Cathy has a Bachelor of Economics (Macquarie University) and a Master of Commerce, Accounting & Law (University of NSW). She is a Graduate of the Australian Institute of Company Directors and a Senior Fellow of the Financial Services Institute of Australasia (FINSIA).
Reported Earnings • Feb 27First half 2024 earnings released: EPS: AU$0.033 (vs AU$0.027 in 1H 2023)First half 2024 results: EPS: AU$0.033 (up from AU$0.027 in 1H 2023). Revenue: AU$125.7m (up 22% from 1H 2023). Net income: AU$12.8m (up 20% from 1H 2023). Profit margin: 10% (in line with 1H 2023). Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, while revenues in the Healthcare industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings.
Declared Dividend • Feb 26First half dividend of AU$0.025 announcedShareholders will receive a dividend of AU$0.025. Ex-date: 7th March 2024 Payment date: 5th April 2024 Dividend yield will be 4.5%, which is higher than the industry average of 3.3%. Sustainability & Growth Dividend is covered by both earnings (73% earnings payout ratio) and cash flows (80% cash payout ratio). The dividend has decreased over the past 96 years, indicating a lack of growth and stability in payments. EPS is expected to grow by 51% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
공시 • Jan 08+ 1 more updateMonash IVF Group Limited to Report First Half, 2024 Results on Feb 23, 2024Monash IVF Group Limited announced that they will report first half, 2024 results on Feb 23, 2024
Upcoming Dividend • Aug 31Upcoming dividend of AU$0.022 per share at 3.5% yieldEligible shareholders must have bought the stock before 07 September 2023. Payment date: 11 October 2023. Payout ratio is on the higher end at 79%, and the cash payout ratio is above 100%. Trailing yield: 3.5%. Lower than top quartile of German dividend payers (4.9%). Higher than average of industry peers (2.9%).
공시 • Aug 22Monash IVF Group Limited Announces Fully Franked Final Dividend for Fiscal Year Ended June 30, 2023, Payable on 11 October 2023Monash IVF Group Limited announced that on 22 August 2023, a fully franked final FY2023 dividend of 2.2 cents per share was declared. The record date for the dividend is 8 September 2023 and the payment date for the dividend is 11 October 2023.
Reported Earnings • Aug 22Full year 2023 earnings released: EPS: AU$0.056 (vs AU$0.047 in FY 2022)Full year 2023 results: EPS: AU$0.056 (up from AU$0.047 in FY 2022). Revenue: AU$213.6m (up 11% from FY 2022). Net income: AU$21.8m (up 19% from FY 2022). Profit margin: 10% (in line with FY 2022). Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 24% per year, which means it is well ahead of earnings.
공시 • Aug 21Monash IVF Group Limited Provides Update on Class Action LawsuitAs announced to the ASX on 23 December 2020, Monash IVF Group Limited became aware that it and certain of its subsidiaries have been named as defendants ("Defendants") in proceedings filed in the Supreme Court of Victoria in relation to, or in connection with, the Group's non-invasive pre-implantation genetic screening technology (Ni-PGT or cell-free PGT-A) ("Class Action"). The plaintiffs in the Class Action have filed an amended statement of claim in relation to the Class Action. The amended statement of claim, amongst other things, seeks payment for aggravated damages and exemplary damages from the Defendants in the Class Action. No amount is specified or estimated in respect of the claim. As previously announced, Monash IVF has notified its insurer. The costs of Monash IVF's defence of the Class Action are currently being funded by its insurer. The amended part of the Class Action relating to aggravated damages and exemplary damages, and the costs of defending that, is uninsured. Legal costs and damages, if any, in excess of insurance proceeds will be funded by Monash IVF. Monash IVF continues to defend these claims and will keep the market updated in regards to its continuous disclosure obligations.
공시 • May 29Monash IVF Group Limited (ASX:MVF) completed the acquisition of PIVET Medical Centre.Monash IVF Group Limited (ASX:MVF) agreed to acquire PIVET Medical Centre for AUD 9.4 million on May 18, 2022. Monash IVF is paying additional earn out payments over a one to two year period from completion. The acquisition is expected to be funded through Monash IVF's operating cash flows and/or debt facilities available. The PIVET brings into the Monash IVF clinician network, 9 fertility specialists who have worked together for several years. Completion is expected to occur during First Quarter 2023, subject to certain conditions precedent. As of August 26, 2022, The transaction is expected to complete by end of September 2022. As of February 21, 2023, the transaction is expected to complete by end of Q3 of FY2023. Squire Patton Boggs (UK) LLP acted as a legal advisor to PIVET Medical Centre. Monash IVF Group Limited (ASX:MVF) completed the acquisition of PIVET Medical Centre on May 29, 2023.
Upcoming Dividend • Mar 01Upcoming dividend of AU$0.022 per share at 4.2% yieldEligible shareholders must have bought the stock before 08 March 2023. Payment date: 06 April 2023. The company is paying out more than 100% of its earnings and cash flow. Trailing yield: 4.2%. Lower than top quartile of German dividend payers (4.7%). Higher than average of industry peers (3.3%).
Reported Earnings • Feb 21First half 2023 earnings released: EPS: AU$0.027 (vs AU$0.031 in 1H 2022)First half 2023 results: EPS: AU$0.027 (down from AU$0.031 in 1H 2022). Revenue: AU$103.3m (up 2.3% from 1H 2022). Net income: AU$10.6m (down 12% from 1H 2022). Profit margin: 10% (down from 12% in 1H 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 9.3% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
공시 • Jan 18+ 2 more updatesMonash IVF Group Limited to Report First Half, 2023 Results on Feb 21, 2023Monash IVF Group Limited announced that they will report first half, 2023 results on Feb 21, 2023
Board Change • Nov 16Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 2 experienced directors. 4 highly experienced directors. Independent Non-Executive Director Catherine West was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Upcoming Dividend • Sep 01Upcoming dividend of AU$0.022 per shareEligible shareholders must have bought the stock before 08 September 2022. Payment date: 07 October 2022. Payout ratio and cash payout ratio are on the higher end at 93% and 83% respectively. Trailing yield: 4.3%. Lower than top quartile of German dividend payers (4.7%). Higher than average of industry peers (3.7%).
Reported Earnings • Aug 27Full year 2022 earnings released: EPS: AU$0.047 (vs AU$0.065 in FY 2021)Full year 2022 results: EPS: AU$0.047 (down from AU$0.065 in FY 2021). Revenue: AU$192.3m (up 4.7% from FY 2021). Net income: AU$18.4m (down 27% from FY 2021). Profit margin: 9.6% (down from 14% in FY 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 13%, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has increased by 4% per year, which means it is well ahead of earnings.
Board Change • Jun 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Non-Executive Director Catherine West was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • May 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 5 experienced directors. 1 highly experienced director. Independent Non-Executive Director Catherine West was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Upcoming Dividend • Sep 02Upcoming dividend of AU$0.021 per shareEligible shareholders must have bought the stock before 09 September 2021. Payment date: 08 October 2021. Trailing yield: 4.2%. Within top quartile of German dividend payers (3.1%). Higher than average of industry peers (2.2%).
Reported Earnings • Aug 25Full year 2021 earnings released: EPS AU$0.065 (vs AU$0.046 in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$183.6m (up 26% from FY 2020). Net income: AU$25.1m (up 115% from FY 2020). Profit margin: 14% (up from 8.1% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
Recent Insider Transactions • May 01Independent Non-Executive Director recently bought €124k worth of stockOn the 26th of April, Neil Broekhuizen bought around 217k shares on-market at roughly €0.57 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €146k more in shares than they have sold in the last 12 months.
Analyst Estimate Surprise Post Earnings • Feb 25Revenue beats expectationsRevenue exceeded analyst estimates by 4.3%. Over the next year, revenue is forecast to grow 6.0%, compared to a 3.4% growth forecast for the Healthcare industry in Germany.
Reported Earnings • Feb 25First half 2021 earnings released: EPS AU$0.037 (vs AU$0.035 in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: AU$90.8m (up 18% from 1H 2020). Net income: AU$14.6m (up 79% from 1H 2020). Profit margin: 16% (up from 11% in 1H 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Feb 18New 90-day high: €0.51The company is up 11% from its price of €0.46 on 19 November 2020. The German market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.56 per share.
Is New 90 Day High Low • Dec 23New 90-day high: €0.48The company is up 39% from its price of €0.34 on 24 September 2020. The German market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.53 per share.
Is New 90 Day High Low • Nov 11New 90-day high: €0.44The company is up 38% from its price of €0.32 on 13 August 2020. The German market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Healthcare industry, which is down 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €0.45 per share.
